Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | ||
| Invokamet | Canagliflozin and metformin hydrochloride | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Basaglar | Insulin glargine | Diabetes mellitus, type 1; diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
| Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
| Tresiba | insulin degludec | Diabetes mellitus, Type 1 & 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete |
Last Updated : May 17, 2024